Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 12Neoplasms 8Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Osteosarcoma 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Advanced Gastric Cancer 2Thyroid Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Quality of Life 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

apatinib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Efficacy and Safety × apatinib × Clear all
NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡